Wedbush Securities Inc. boosted its holdings in Sanofi SA (NYSE:SNY) by 8.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 15,888 shares of the company’s stock after buying an additional 1,221 shares during the period. Wedbush Securities Inc.’s holdings in Sanofi were worth $687,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of SNY. Ibex Wealth Advisors purchased a new stake in Sanofi in the 2nd quarter worth $25,000. Bessemer Group Inc. increased its stake in Sanofi by 292.4% in the 2nd quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after buying an additional 500 shares in the last quarter. Nkcfo LLC purchased a new stake in Sanofi in the 1st quarter worth $35,000. Cullen Frost Bankers Inc. purchased a new stake in Sanofi in the 1st quarter worth $35,000. Finally, Howe & Rusling Inc. purchased a new stake in Sanofi in the 1st quarter worth $38,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
A number of brokerages have issued reports on SNY. UBS Group upgraded Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $51.00.
SNY traded up $0.01 on Thursday, hitting $41.75. The company had a trading volume of 18,552 shares, compared to its average volume of 1,242,809. The firm has a market cap of $103.37 billion, a P/E ratio of 13.35, a PEG ratio of 2.41 and a beta of 0.67. Sanofi SA has a 12-month low of $40.00 and a 12-month high of $45.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The company’s fifty day moving average is $42.25.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 29th. The company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.07. The company had revenue of $8.63 billion during the quarter, compared to analyst estimates of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted $1.25 earnings per share. On average, sell-side analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Percentage Decliners
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.